Strategic Partnership Explore post-acquisition collaboration with Pfizer or successor entities to leverage Trillium's CD47 immuno-oncology programs, focusing on decoy receptor approaches that complement Pfizer’s oncology portfolio and existing commercialization capabilities.

Clinical-stage Advantage Position Trillium as a niche partner for late-stage or phase promoting deals in immune-oncology, offering access to a focused CD47 decoy receptor program that may accelerate co-development or licensing discussions with larger bio-pharma players seeking novel checkpoint strategies.

Rare Size Premium Target mid-market biotechs and specialty oncology developers, highlighting Trillium’s lean organization, focused pipeline, and outsized potential return for partnerships that can scale with Pfizer-level resources through milestone-driven collaborations.

Funding Leverage Leverage the substantial historical funding and modest current revenue to propose cost-efficient collaboration models (milestone-heavy, risk-sharing) that align with potential acquirers or licensees looking to augment their immuno-oncology portfolios without upfront capital heavy commitments.

Market Fit Signals Identify opportunities with companies pursuing CD47 or checkpoint inhibitor strategies, and propose co-development or out-license options that capitalize on Trillium’s immuno-oncology focus, clinical-stage status, and demonstrated interest from major pharma players.